These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 29411654)
21. Review on the clinical use of eribulin mesylate for the treatment of breast cancer. Aseyev O; Ribeiro JM; Cardoso F Expert Opin Pharmacother; 2016; 17(4):589-600. PubMed ID: 26809667 [TBL] [Abstract][Full Text] [Related]
22. Eribulin: rediscovering tubulin as an anticancer target. Jimeno A Clin Cancer Res; 2009 Jun; 15(12):3903-5. PubMed ID: 19509144 [TBL] [Abstract][Full Text] [Related]
23. Eribulin mesylate: mechanism of action of a unique microtubule-targeting agent. Dybdal-Hargreaves NF; Risinger AL; Mooberry SL Clin Cancer Res; 2015 Jun; 21(11):2445-52. PubMed ID: 25838395 [TBL] [Abstract][Full Text] [Related]
24. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Schöffski P; Ray-Coquard IL; Cioffi A; Bui NB; Bauer S; Hartmann JT; Krarup-Hansen A; Grünwald V; Sciot R; Dumez H; Blay JY; Le Cesne A; Wanders J; Hayward C; Marreaud S; Ouali M; Hohenberger P; Lancet Oncol; 2011 Oct; 12(11):1045-52. PubMed ID: 21937277 [TBL] [Abstract][Full Text] [Related]
25. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. Kawano S; Asano M; Adachi Y; Matsui J Anticancer Res; 2016 Apr; 36(4):1553-61. PubMed ID: 27069131 [TBL] [Abstract][Full Text] [Related]
26. The European medicines agency review of eribulin for the treatment of patients with locally advanced or metastatic breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Pean E; Klaar S; Berglund EG; Salmonson T; Borregaard J; Hofland KF; Ersbøll J; Abadie E; Giuliani R; Pignatti F Clin Cancer Res; 2012 Sep; 18(17):4491-7. PubMed ID: 22829199 [TBL] [Abstract][Full Text] [Related]
27. Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma? Ratan R; Patel SR Curr Treat Options Oncol; 2017 Jun; 18(6):34. PubMed ID: 28534249 [TBL] [Abstract][Full Text] [Related]
28. Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer. Twelves C; Cortes J; Vahdat LT; Wanders J; Akerele C; Kaufman PA Clin Breast Cancer; 2010 Apr; 10(2):160-3. PubMed ID: 20299316 [TBL] [Abstract][Full Text] [Related]
29. A case of heavily pretreated metastatic cardiac angiosarcoma treated successfully using eribulin. Inagaki C; Shimoi T; Okuma H; Kitano A; Shimomura A; Noguchi E; Kodaira M; Yunokawa M; Yonemori K; Shimizu C; Yoshida A; Fujiwara Y; Tamura K Anticancer Drugs; 2018 Jan; 29(1):97-101. PubMed ID: 29176397 [TBL] [Abstract][Full Text] [Related]
31. Perspectives on the mechanism of action and clinical application of eribulin for metastatic breast cancer. O'Shaughnessy J; Kaklamani V; Kalinsky K Future Oncol; 2019 May; 15(14):1641-1653. PubMed ID: 30892083 [TBL] [Abstract][Full Text] [Related]
32. Eribulin in advanced breast cancer: safety, efficacy and new perspectives. Garrone O; Miraglio E; Vandone AM; Vanella P; Lingua D; Merlano MC Future Oncol; 2017 Dec; 13(30):2759-2769. PubMed ID: 29219017 [TBL] [Abstract][Full Text] [Related]
33. A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Goel S; Mita AC; Mita M; Rowinsky EK; Chu QS; Wong N; Desjardins C; Fang F; Jansen M; Shuster DE; Mani S; Takimoto CH Clin Cancer Res; 2009 Jun; 15(12):4207-12. PubMed ID: 19509177 [TBL] [Abstract][Full Text] [Related]
34. Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer. Newman S Curr Opin Investig Drugs; 2007 Dec; 8(12):1057-66. PubMed ID: 18058576 [TBL] [Abstract][Full Text] [Related]
35. Advances in the treatment of soft tissue sarcoma: focus on eribulin. Koliou P; Karavasilis V; Theochari M; Pollack SM; Jones RL; Thway K Cancer Manag Res; 2018; 10():207-216. PubMed ID: 29440930 [TBL] [Abstract][Full Text] [Related]
36. Population pharmacometric analyses of eribulin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes. Majid O; Gupta A; Reyderman L; Olivo M; Hussein Z J Clin Pharmacol; 2014 Oct; 54(10):1134-43. PubMed ID: 24771603 [TBL] [Abstract][Full Text] [Related]
37. Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cortes J; Montero AJ; Glück S Cancer Treat Rev; 2012 Apr; 38(2):143-51. PubMed ID: 21550727 [TBL] [Abstract][Full Text] [Related]
38. The clinical outcome of eribulin treatment in Japanese patients with advanced soft tissue sarcoma: a Tokai Musculoskeletal Oncology Consortium study. Nakamura T; Tsukushi S; Asanuma K; Katagiri H; Ikuta K; Nagano A; Kozawa E; Yamada S; Shido Y; Yamada K; Kawanami K; Ishimura D; Sudo A; Nishida Y Clin Exp Metastasis; 2019 Aug; 36(4):343-350. PubMed ID: 31209624 [TBL] [Abstract][Full Text] [Related]
39. Pre-treatment Neutrophil-to-Lymphocyte Ratio Predicts Efficacy of Eribulin for Soft-tissue Sarcoma. Sato Y; Nakano K; Fukuda N; Wang X; Urasaki T; Ohmoto A; Yunokawa M; Ono M; Tomomatsu J; Hayakawa K; Funauchi Y; Tanizawa T; Ae K; Matsumoto S; Takahashi S Anticancer Res; 2021 Jan; 41(1):527-532. PubMed ID: 33419852 [TBL] [Abstract][Full Text] [Related]